Bayer AG
Life sciences company in pharmaceuticals, consumer health, and crop science
of 100 · unstable trend · Some good traits but inconsistent
Standing
51/100
Raw Score
43/85
Confidence
82%
Evidence
Strong
About
Bayer is a globally influential life-sciences company whose medicines, consumer-health products, contraception access work, and agricultural technologies create substantial public benefit. Its goodness alignment is constrained by severe historical responsibility through I.G. Farben, long-running glyphosate/Roundup and Monsanto-linked litigation, pesticide and environmental-rights allegations, and a frequent reliance on legal containment under pressure.
The observable record shows a company with mature compliance, sustainability reporting, and real access-to-health programs, but also a high-impact risk profile in agriculture and product safety. Bayer’s moral signal is mixed: meaningful service capacity and institutional discipline are visible, while trust and integrity remain weakened by unresolved harm narratives and contested accountability.
Five Pillars
Pillar scores (0–100%)
Bayer combines real social benefit and disciplined reporting with severe historical harm, current pesticide controversies, and an often defensive legal posture under pressure.
Goodness over time
Starts at 100 at birth, natural decay after accountability age, timeline events adjust the trajectory.
17 Criteria Scores
Individual item scores (0–5) with evidence notes
Core Worldview
Bayer is secular and frames purpose through science, health, hunger, and sustainability rather than explicit devotion.
Long-horizon research, stewardship language, and sustainability systems show an institutional belief in ordered responsibility.
Institutional guidance is corporate, legal, and scientific rather than faith-revealed.
Bayer uses founders, scientists, and patients as exemplars rather than prophetic moral models.
Reporting and governance show accountability orientation, but historical and current controversies limit the score.
Contribution to Others
The company serves proximate stakeholders through employment, medicines, consumer health, and farmer support.
Family-planning and public-health programs indirectly support youth and women, but this is not the company’s defining beneficiary group.
Access-to-medicine, contraception, self-care, and smallholder programs show real benefit in underserved communities.
Global reach is significant, but most aid flows through product markets and programs rather than direct care for disconnected people.
Speak-up and grievance channels exist, while Roundup and pesticide controversies raise concerns about remedy for harmed stakeholders.
Products can reduce disease and food constraints, but pesticide and safety controversies prevent a stronger liberation signal.
Personal Discipline
Institutional discipline is visible through compliance, sustainability reporting, and structured governance systems.
Structured access, foundation, family-planning, and public-health programs show disciplined social obligation, even within a commercial model.
Reliability
Formal transparency is mature, but litigation, Monsanto-linked liabilities, and contested community impacts weaken trust.
Stability Under Pressure
The company remains institutionally stable despite historical scrutiny and reputational pressure.
Bayer is restructuring, reducing debt, and investing in R&D under heavy litigation and market pressure.
Under pressure Bayer often emphasizes legal defense and liability limitation, which limits the moral resilience score.
Timeline
Key events and documented turning points
Bayer founded as a dyestuffs company
Friedrich Bayer and Johann Friedrich Weskott founded the company that later became Bayer AG, beginning a long industrial life-sciences history.
→ Created a major German life-sciences institution with global reach.
highBayer assets transferred into I.G. Farben
Bayer became part of I.G. Farben, the chemical conglomerate later implicated in Nazi war production and forced labor.
→ Bayer’s predecessor identity became tied to one of the most serious corporate responsibility legacies in modern history.
severeForced labor used at I.G. Farben Lower Rhine sites
Bayer’s own history states that from 1940 onward I.G. Farben used forced laborers from occupied Europe at Lower Rhine sites, with around 16,000 people deployed under discriminatory and inhumane conditions.
→ Severe violation of human dignity and worker rights in Bayer’s predecessor structure.
severeBayer acquired Monsanto
Bayer acquired Monsanto, expanding crop science but also absorbing major glyphosate, PCB, seed, pesticide, and agricultural-governance controversies.
→ Increased Bayer’s agricultural reach while sharply increasing litigation and reputational risk.
highBayer ranked 10th in Access to Medicine Index
The Access to Medicine Foundation ranked Bayer 10th of 20 major research-based pharmaceutical companies, noting strong governance of access and broad LMIC product registration, while also noting limited outcomes data for some access strategies.
→ Independent evidence of meaningful but still incomplete access-to-medicine alignment.
mediumCivil-society OECD complaint challenged Bayer’s soy and pesticide due diligence
A civil-society coalition alleged that Bayer’s GM soy and pesticide business in South America was linked to human-rights and environmental harms. Bayer rejected core allegations and said it had not received reports matching the complainants’ claims.
→ Created a contested but serious due-diligence pressure test around Bayer’s agricultural model.
highBayer reported 2025 sales, R&D investment, and turnaround progress
Bayer reported €45.6 billion in 2025 sales, €9.7 billion EBITDA before special items, €5.8 billion R&D investment, and 88,078 employees, while emphasizing debt reduction, pharma pipeline growth, crop-science restructuring, and litigation containment.
→ Demonstrated operating resilience and continued innovation investment under financial and legal pressure.
highU.S. Supreme Court ruling favored Bayer in Roundup failure-to-warn litigation
The U.S. Supreme Court sided with Bayer/Monsanto on federal preemption for Roundup failure-to-warn claims, a ruling expected to block thousands of lawsuits. Bayer still planned to proceed with a proposed $7.25 billion settlement for many remaining claims, while health and environmental advocates criticized the ruling.
→ Reduced major litigation exposure but intensified debate over accountability, product safety, and access to remedy.
severePressure Tests
Behavior under crisis or scrutiny
I.G. Farben forced-labor and Holocaust-era responsibility
1940Bayer’s predecessor structure within I.G. Farben used forced labor under inhumane and discriminatory conditions during World War II.
Response: Modern Bayer publicly documents this history and maintains a memorial, but the harm remains severe and irreparable.
redMonsanto acquisition and Roundup litigation
2018Bayer absorbed Monsanto-linked litigation and has faced massive Roundup failure-to-warn claims.
Response: The company disputes cancer allegations, pursued settlement and legal strategies, and obtained a major U.S. Supreme Court preemption ruling in 2026.
orangeOECD complaint over South American soy and pesticide impacts
2024Civil-society groups alleged human-rights and environmental harms linked to Bayer’s agricultural model.
Response: Bayer rejected the allegations and pointed to due diligence, product stewardship, and lack of direct reports matching the claims.
orangeProgression
crisis years
Monsanto acquisition, glyphosate litigation, and pesticide controversies put accountability under sustained pressure.
unstablecurrent stage
Bayer is rebuilding through restructuring, access programs, compliance systems, and litigation containment, but the moral record remains mixed.
unclearearly years
Scientific and industrial growth created a globally important healthcare and chemical platform.
risinggrowth years
Growth brought both public benefit and severe historical entanglement through I.G. Farben.
mixedBehavioral Patterns
Positive
- • Large-scale health, contraception, and agricultural capabilities can materially improve lives when access and safety are well governed.
- • Public sustainability, human-rights, compliance, and access-to-medicine systems are comparatively mature and externally assessable.
- • Bayer has shown resilience through restructuring, debt reduction, and continued R&D investment under litigation pressure.
Concerns
- • I.G. Farben forced-labor history remains a severe institutional legacy requiring ongoing remembrance and accountability.
- • Monsanto/Roundup litigation and glyphosate controversy continue to weaken trust in product stewardship and remedy.
- • Civil-society allegations around pesticides, soy, deforestation, and community harms show unresolved environmental-justice concerns.
Evidence Quality
8
Strong
4
Medium
0
Weak
Overall: strong
This profile evaluates observable institutional conduct, not hidden intentions or private belief.